非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析*

doi:10.3969/j.issn.1672-5069.2022.04.017

Abstract

Abstract: Objective The aim of this study was to screen plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases (NAFLD) and analyze their roles in biological processes. Methods Three patients with NAFLD and three healthy individuals were encountered in You'an Hospital, Capital Medical University between July and October 2020. The plasma exosome proteins were identified and quantitatively characterized by tandem mass tag (TMT) labeled quantitative proteomics. The differential proteins and their functional enrichment were screened, and the biological processes involved were analyzed. Results A total of 387 proteins were identified by exosome proteomic analysis, and out of them, 34 differentially expressed proteins were screened out according to the criteria of up-regulation > 1.2 folds or down-regulation > 1.2 folds and P<0.05; 25 up-regulation proteins and 9 down-regulation proteins were found in patients with NAFLD compared with healthy persons; the bioinformatics analysis showed that these proteins were mainly involved in lipid storage and metabolism, immune response, cellulose formation and other biological processes, and were closely related to insulin resistance, inflammatory response, cell damage and other signaling pathways. Conclusion The differential proteins screened by TMT marker quantitative proteomics might be used as serological markers for the study of NAFLD.

Key words: Nonalcoholic fatty liver disease, Exosome, Differential protein, Proteomics

Zhang Wenyan, Liu Fang, Liu Menglu, et al. Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(4): 521-525.

References

[1] McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol,2015,62(5):1148-1155.
[2] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018,15(1):11-20.
[3] Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res,2014,24(6):766-769.
[4] Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv,2018,36(1):328-334.
[5] Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol,2007,9(6):654-659.
[6] Kornek M, Lynch M, Mehta SH, et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology,2012,143(2): 448-458.
[7] Hirsova P, Ibrahim SH, Verma VK, et al. Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology,2016,64(6): 2219-2233.
[8] Tyanova S, Temu T, Sinitcyn P, et al. The perseus computational platform for comprehensive analysis of (prote)omics data. Nature Methods,2016,13(9): 731-740.
[9] Geis-Asteggiante L, Belew AT, Clements VK, et al. Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J Proteome Res,2018,17(1):486-498.
[10] Tkach M, Thery C. Communication by extracellular vesicles: Where we are and where we need to go. Cell,2016,164(6):1226-1232.
[11] Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: A web-based compendium of exosomal cargo. J Mol Biol,2016,428(4):688-692.
[12] Eguchi T, Sogawa C, Okusha Y, et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. PLOS One,2018,13(2):e191109.
[13] Rosa-Fernandes L, Rocha VB, Carregari VC, et al. A perspective on extracellular vesicles proteomics. Front Chem,2017,5:102.
[14] Sinha A, Principe S, Alfaro J, et al. Proteomic profiling of secreted proteins, exosomes, and microvesicles in cell culture conditioned media. Methods Mol Biol,2017,1722:91-102.
[15] Atay S, Wilkey DW, Milhem M, et al. Insights into the proteome of gastrointestinal stromal tumors-derived exosomes reveals new potential diagnostic biomarkers. Mol Cell Proteomics,2018,17(3):495-515.
[16] Intasqui P, Bertolla RP, Sadi MV. Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics,2018,15(1): 65-79.
[17] Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev,2007,65(5):251-256.
[18] Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol,2009,7(5):575-579.
[19] Tan Y, Sun LQ, Kamal MA, et al. Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochim Biophys Acta,2011,1811(12): 1045-1053.
[20] Seiffert D, Keeton M, Eguchi Y, et al. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA,1991,88(21):9402-9406.

Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Qing, Zhang Lili. When T2DM comes across with NAFLD:1+1＞2？ [J]. Journal of Practical Hepatology, 2022, 25(4): 460-463.
[2]	Cai Dongmei, Wu Wenjuan, Jiang Yilun, et al. Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque [J]. Journal of Practical Hepatology, 2022, 25(3): 383-386.
[3]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[4]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[5]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[6]	Lyu Chunhui, Li Dawei, Wang Xiaojie, et al. Short-term impact of metformin an simvastatin combination therapy on blood glucose and lipid parameters in patients with nonalcoholic fatty liver disease with concomitant diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 50-53.
[7]	Jia Kun, Su Jianrong, Sun Wei. Clinical implication of LncRNA HEIH in serum and exosomes in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 823-826.
[8]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[9]	Zhang Yizhi, Zhang Xiaohui, Chen Yu. Models of nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(5): 761-764.
[10]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[11]	Luo Weixin, Liu Chaoqun, Xu Leibo, et al. Effects of exosomes derived from rat liver cancer cells with different lung metastasis potentials on the transcriptome of macrophages [J]. Journal of Practical Hepatology, 2021, 24(3): 312-318.
[12]	Chen Xi, Wang Wei, Gao Jianwei, et al. Impact of antiviral therapy efficacy of entecavir in patients with chronic hepatitis B and concomitant nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 343-346.
[13]	Jia Qunling, Xu Zhibin, Han Shu. Implication of magnetic resonanceimaging-proton density fat fraction in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 359-362.
[14]	Liu Xiangji, Liu Zhenxian, Wang Xiaoyan. Incidence of gallstone disease in middle-aged and elderly patients with nonalcoholic fatty liver disease and its relation to metabolic risk factors [J]. Journal of Practical Hepatology, 2021, 24(3): 363-366.
[15]	Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage [J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.